C H Smorenburg

Summary

Country: The Netherlands

Publications

  1. ncbi request reprint Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients
    C H Smorenburg
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
    Anticancer Drugs 11:825-8. 2000
  2. ncbi request reprint Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane
    C H Smorenburg
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
    Breast Cancer Res Treat 66:83-7. 2001
  3. ncbi request reprint Combination chemotherapy of the taxanes and antimetabolites: its use and limitations
    C H Smorenburg
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, University Hospital Rotterdam, Rotterdam, The Netherlands
    Eur J Cancer 37:2310-23. 2001
  4. ncbi request reprint Capecitabine in breast cancer: current status
    C H Smorenburg
    Rotterdam Cancer Institute Daniel den Hoed Kliniek, University Hospital Rotterdam, Rotterdam, The Netherlands
    Clin Breast Cancer 1:288-93; discussion 294. 2001
  5. ncbi request reprint Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial
    A J ten Tije
    Department of Medical Oncology, Erasmus MC Rotterdam Cancer Institute m Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Eur J Cancer 40:352-7. 2004
  6. ncbi request reprint Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer
    C H Smorenburg
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 39:196-202. 2003
  7. ncbi request reprint Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase
    C H Smorenburg
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Ann Oncol 17:35-42. 2006
  8. ncbi request reprint FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer
    N Croles
    Department of Medical Oncology, Free University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Neth J Med 62:242-5. 2004
  9. ncbi request reprint Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands
    C H Smorenburg
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Neth J Med 65:132-6. 2007

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients
    C H Smorenburg
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
    Anticancer Drugs 11:825-8. 2000
    ..9 months. In this study topically applied miltefosine for metastatic skin lesions of breast cancer showed modest activity in a relatively heavily pretreated patient population, without serious systemic toxicity...
  2. ncbi request reprint Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane
    C H Smorenburg
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
    Breast Cancer Res Treat 66:83-7. 2001
    ..Gemcitabine is ineffective as third-line single agent therapy in patients failing anthracycline and taxane treatment for metastatic breast cancer...
  3. ncbi request reprint Combination chemotherapy of the taxanes and antimetabolites: its use and limitations
    C H Smorenburg
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, University Hospital Rotterdam, Rotterdam, The Netherlands
    Eur J Cancer 37:2310-23. 2001
    ....
  4. ncbi request reprint Capecitabine in breast cancer: current status
    C H Smorenburg
    Rotterdam Cancer Institute Daniel den Hoed Kliniek, University Hospital Rotterdam, Rotterdam, The Netherlands
    Clin Breast Cancer 1:288-93; discussion 294. 2001
    ..It is currently registered in various countries for use in third-line treatment of metastatic disease. Its further role will have to be defined from data of randomized phase III studies...
  5. ncbi request reprint Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial
    A J ten Tije
    Department of Medical Oncology, Erasmus MC Rotterdam Cancer Institute m Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Eur J Cancer 40:352-7. 2004
    ..Weekly paclitaxel at this dose and schedule is an effective treatment regimen in the elderly patient with metastatic breast cancer, and is feasible, but yields relevant fatigue in a subset of patients...
  6. ncbi request reprint Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer
    C H Smorenburg
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 39:196-202. 2003
    ..The clinical relevance of these observations with respect to toxicity profiles and antitumour efficacy requires further evaluation...
  7. ncbi request reprint Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase
    C H Smorenburg
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Ann Oncol 17:35-42. 2006
    ..We performed a prospective study in which the choice of first-line chemotherapy with either 5-FU or a non-5-FU containing regimen was based on TS and DPD expression...
  8. ncbi request reprint FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer
    N Croles
    Department of Medical Oncology, Free University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Neth J Med 62:242-5. 2004
    ..The combination of oxaliplatin, 5-fluorouracil (5FU) and leucovorin (LV) has shown to be active and safe as first- or second-line chemotherapy for metastatic colorectal cancer (MCC)...
  9. ncbi request reprint Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands
    C H Smorenburg
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Neth J Med 65:132-6. 2007
    ..Ewing's sarcoma and peripheral primitive neuroectodermal tumours (PNET) are rare tumours and closely related. They occur most often in children and adolescents. Few studies have been published on treatment outcome in adult patients...